BLP does not alter inflammatory chemokine production in the skin. (A,B) D6-deficient mice were given intraperitoneal BLP (100 μg) or vehicle injections, TPA was applied to skin and mice culled 24 hours later. Skins were removed, lysed, and levels of CCL3 (A) and CXCL2 (B) were measured by the use of ELISA and compared with levels detectable in untreated control mouse skin. These data are representative of 2 separate experiments with 3 to 5 mice per group. (C,D) Primary cultures of bone marrow–derived macrophages (C) and anti-CD3 primed CD4⁺ T cells from D6-deficient mice (D) were stimulated with 100 ng/mL BLP for 4 hours in complete RPMI, RNA extracted, and transcripts for CCL3 and IL-6 quantified by qPCR and expressed as fold change relative to unstimulated cultures. Bars show the mean of 4 replicates plus or minus SEM. Marked bars are statistically different from control unstimulated cells (Student t test; *P < .01). (E) BLP (100 μg) was administered intraperitoneally to D6-deficient mice, and blood was collected and plasma prepared 6 and 24 hours later. Chemokine levels in the plasma were assayed by Luminex. These data are mean average measurements from 3 mice per point ± SD.